Eva Rubio-Marrero, Ph.D.Senior Scientist at Bristol Myers Squibb
Eva Rubio-Marrero, Ph.D., works at Bristol Myers Squibb (BMS) in New Jersey site in the Cell Line Development and ‘Omics group in the Biologics Department. She helped to develop the CLD platform in Celgene company before it was acquired by BMS in 2019 and has worked with multiple projects for monoclonal and bispecific antibodies. Prior to Celgene (now BMS), Eva was pursuing her doctoral degree where she had the opportunity to develop cell lines expressing proteins linked to autism spectrum disorders (ASD) in mammalian system and studied the function of these proteins in the nervous system. Eva continues contributing to CLD exploring new technologies that helps overcome challenges in the CLD process.